Lone Star owns 75% of Novo Banco, and Portugal’s government holds 25% through entities including the country’s Resolution Fund, which is run by the Bank of Portugal. Novo Banco is a long ...

(Bloomberg) -- Novo Banco SA, a Portuguese lender that’s majority-owned by US private equity firm Lone Star, has selected banks to arrange an initial public offering, according to people familiar with ...

LISBON, Feb 13 (Reuters) - Portugal's Novo Banco has begun preparations for an initial public offering (IPO) that could be one of the largest in Europe this year, tapping into a surge in ...

LISBON (Reuters) - U.S. private equity firm Lone Star has told the Portuguese government that it is likely to sell a 25-30% stake in Novo Banco via an initial public offering, rather than seek a full ...

LISBON, Feb 12 (Reuters) - Portugal's banking resolution fund aims to sell its 13.54% stake in Novo Banco at the best possible price to maximise revenues, the fund's chief Luis Maximo dos Santos ...

US private equity firm Lone Star has indicated to the Portuguese government its plans to sell a 25-30% stake in Novo Banco via an initial public offering (IPO), according to Portugal Finance ...

Santander's Portuguese bank is not interested in buying Novo Banco, its CEO Pedro Castro Almeida said on Friday, as its strategy will be to focus on organic growth. Almeida said in November that ...

LISBON (Reuters) - Portugal's banking resolution fund aims to sell its 13.54% stake in Novo Banco at the best possible price ...

Novo Nordisk announced phase 1b/2a clinical trial results for amycretin this morning. Patients taking the GLP-1 drug lost an average of 9.7% of their weight in 36 weeks. This is the best news Novo ...

Novo Nordisk has reported 22% weight loss in people who received weekly amycretin injections for 36 weeks, triggering an 11% jump in the Danish drugmaker’s share price in premarket trading.

Novo Nordisk A/S rose the most since August 2023 after its experimental shot delivered as much as 22% weight loss in an early-stage trial, boosting investors’ hopes for the drugmaker’s pipeline.

In a report released today, Jo Walton from UBS maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of DKK750.00. The company’s shares closed yesterday at ...